Iwona Palyga

Iwona Palyga

S. Artwińskiego St. 3
Kielce, SK 25734, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Radioactive iodine (¹³¹I) therapy in a patient with unresectable papillary thyroid cancer: when palliative treatment becomes neoadjuvant.

Radioactive iodine (¹³¹I) therapy in a patient with unresectable papillary thyroid cancer: when palliative treatment becomes neoadjuvant.

Journal: Endokrynologia Polska

Published: April 23, 2026

Neoadjuvant therapy of unresectable anaplastic thyroid cancer.

Neoadjuvant therapy of unresectable anaplastic thyroid cancer.

Journal: Endokrynologia Polska

Published: August 23, 2025

Elevated Levels of sLAG-3 as a Possible Biomarker in Graves' Disease With and Without Thyroid Eye Disease: A Prospective Observational Case-Control Study.

Elevated Levels of sLAG-3 as a Possible Biomarker in Graves' Disease With and Without Thyroid Eye Disease: A Prospective Observational Case-Control Study.

Journal: Medicina (Kaunas, Lithuania)

Published: August 19, 2025

Association between clinical activity score and serum sPD-1 and sPD-L1 levels during systemic glucocorticoid treatment for active moderate-to-severe thyroid eye disease.

Association between clinical activity score and serum sPD-1 and sPD-L1 levels during systemic glucocorticoid treatment for active moderate-to-severe thyroid eye disease.

Journal: Cytokine

Published: November 11, 2024

Risk characteristics of papillary thyroid cancer > 1-4 cm is associated with increased tumour size.

Risk characteristics of papillary thyroid cancer > 1-4 cm is associated with increased tumour size.

Journal: Clinical and experimental medicine

Published: November 10, 2024

Relationship between the Expression of CHK2 and p53 in Tumor Tissue and the Course of Papillary Thyroid Cancer in Patients with CHEK2 Germline Mutations.

Relationship between the Expression of CHK2 and p53 in Tumor Tissue and the Course of Papillary Thyroid Cancer in Patients with CHEK2 Germline Mutations.

Journal: Cancers

Published: December 28, 2023

The Frequency of Differentiated Thyroid Cancer Recurrence in 2302 Patients With Excellent Response to Primary Therapy.

The Frequency of Differentiated Thyroid Cancer Recurrence in 2302 Patients With Excellent Response to Primary Therapy.

Journal: The Journal of clinical endocrinology and metabolism

Published: June 01, 2023

CD276 as a Candidate Target for Immunotherapy in Medullary Thyroid Cancer.

CD276 as a Candidate Target for Immunotherapy in Medullary Thyroid Cancer.

Journal: International journal of molecular sciences

Published: May 04, 2023

A Significance of Concomitant BRAFV600E and TERT Mutations in Polish Patients with Papillary Thyroid Microcarcinoma: A Retrospective Cohort Study Based on 430 Cases.

A Significance of Concomitant BRAFV600E and TERT Mutations in Polish Patients with Papillary Thyroid Microcarcinoma: A Retrospective Cohort Study Based on 430 Cases.

Journal: Thyroid : official journal of the American Thyroid Association

Published: August 11, 2022

Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy.

Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy.

Journal: Genes

Published: July 29, 2021

Is Male Sex A Prognostic Factor in Papillary Thyroid Cancer?

Is Male Sex A Prognostic Factor in Papillary Thyroid Cancer?

Journal: Journal of clinical medicine

Published: May 13, 2021

Incidence of the CHEK2 Germline Mutation and Its Impact on Clinicopathological Features, Treatment Responses, and Disease Course in Patients with Papillary Thyroid Carcinoma.

Incidence of the CHEK2 Germline Mutation and Its Impact on Clinicopathological Features, Treatment Responses, and Disease Course in Patients with Papillary Thyroid Carcinoma.

Journal: Cancers

Published: December 19, 2020

Showing 1-12 of 34

Last Updated: 09/26/2026